OmniAb Announces Two New Appointments to Its Board of Directors
UniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Capricor Therapeutics | 10-K: FY2024 Annual Report
Capricor Therapeutics' Earnings Call Highlights Progress and Challenges
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $30
Capricor Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Piper Sandler Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Express News | Capricor Therapeutics Shares Are Trading Higher After the Company Reported Q4 Financial Results and Beat Its EPS and Revenue Estimates. HC Wainwright & Co. Reiterated a Buy on the Stock and Cantor Fitzgerald Maintained an Overweight Rating
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Capricor Therapeutics Price Target Maintained With a $30.00/Share by Cantor Fitzgerald
Q4 2024 Capricor Therapeutics Inc Earnings Call
Piper Sandler Remains a Buy on Capricor Therapeutics (CAPR)
Express News | HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
Capricor Therapeutics Analyst Ratings